DocWire News Editors

DocwireNews

Chronic lymphocytic leukemia (CLL) is a disease of older adults, with a median age of onset of about 70 years. Chemoimmunotherapy has become the gold standard of treatment, with the addition of CD20 antibody to chemotherapy prolonging survival. A study presented at the ASH annual meeting sought to compare standard chemoimmunotherapy against targeted therapy with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib. The study also sought to evaluate the benefit of adding rituximab to ibrutinib in this patient population.
Ibrutinib has been approved by the U.S. Food and Drug Administration for use in untreated CLL since 2016. The Alliance A041202 study, a multicenter National Cancer Institute National Clinical Trials Network phase III study, evaluated ibrutinib against chemoimmunotherapy using three randomized arms:
<ul>
<li>arm 1: the standard, aggressive chemoimmunotherapy regimen of bendamustine plus rituximab (BR)</li>
<li>arm 2: ibrutinib alone</li>
<li>arm 3: a combination of ibrutinib plus rituximab</li>
</ul>
Lead author Jennifer A. Woyach, MD, of Ohio State University Comprehensive Cancer Center in Columbus, Ohio, and her coauthors from Canada and many sites throughout the United States, examined differences in progression-free survival (PFS) among the three groups. They included patients who were 65 years or older with previously untreated CLL that was symptomatic. The sample had no other significant life-limiting illnesses. The median age of the initial sample was 71 years, and 67% of the patients were men.
The eligible sample included in the primary analysis was composed of 525 patients (Arm 1 = 176, Arm 2 = 178, and Arm 3 = 171). At a median follow-up of 32 months, median PFS was 41 months in Arm 1 but had not been reached in Arms 2 or 3. The researchers estimated two-year PFS to be 74% in Arm 1, 87% in Arm 2, and 88% in Arm 3. Of note, patients in Arm 1 could cross over to Arm 2 upon progression. The study had not yet found significant differences in overall survival. Median overall survival had not yet been reached in any arm.
When comparing treatment-emergent adverse events (AEs) among the three arms:
<ul>
<li>arm 1:
<ul>
<li>grade 3 or higher hematologic AEs: 61%</li>
<li>grade 3 or higher non-hematologic AEs: 60%</li>
<li>grade 5 AEs: 2.8%</li>
<li>unexplained or unwitnessed death: 1.1%</li>
</ul>
</li>
<li>arm 2:
<ul>
<li>grade 3 or higher hematologic AEs: 41%</li>
<li>grade 3 or higher non-hematologic AEs: 72%</li>
<li>grade 5 AEs: 7.8%</li>
<li>unexplained or unwitnessed death: 3.9%</li>
</ul>
</li>
<li>arm 3:
<ul>
<li>grade 3 or higher hematologic AEs: 38%</li>
<li>grade 3 or higher non-hematologic AEs: 71%</li>
<li>grade 5 AEs: 7.7%</li>
<li>unexplained or unwitnessed death: 2.2%</li>
</ul>
</li>
</ul>
The authors concluded that ibrutinib led to overall better PFS over chemoimmunotherapy in older patients with CLL, supporting its use as standard treatment. They did not find that the addition of rituximab to ibrutinib increased PFS, but they wrote that toxicities and cost limit ibrutinib’s continuous use over the long term.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Study: Ibrutinib Produces Superior PFS to Standard Chemoimmunotherapy in Older Patients with CLL

ASH Annual Meeting 2018

Chronic lymphocytic leukemia (CLL) is a disease of older adults, with a median age of onset of about 70 years. Chemoimmunotherapy has become the gold standard of treatment, ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe